ARWR
ARWR clinical trials: ARROWHEAD PHARMACEUTICALS, INC.
Every trial on ClinicalTrials.gov where ARROWHEAD PHARMACEUTICALS, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 52
- Trials linked
- 50
- As lead sponsor
- 2
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
ARWR on the catalyst calendar · ARWR registry changes
- Primary completion Jun 2027Sponsor estimatePhase 1/Phase 2NCT07221344Trial of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease or Primary TauopathiesArrowhead Pharmaceuticals · Alzheimer DiseaseRecruitingARWRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 15, 2027Sponsor estimatePhase 1/Phase 2NCT06700538A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes MellitusArrowhead Pharmaceuticals · ObesityActive, not recruitingARWRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2028Sponsor estimatePhase 3NCT07473843Study of Zodasiran in Adolescent Participants With Homozygous Familial HypercholesterolemiaArrowhead Pharmaceuticals · Homozygous Familial HypercholesterolemiaRecruitingARWRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2027Sponsor estimatePhase 1/Phase 2NCT07223658Study of ARO-DIMERPA in Adult Participants With Mixed HyperlipidemiaArrowhead Pharmaceuticals · Hyperlipidemia; MixedRecruitingARWRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 17, 2026ActualPhase 3NCT06347016Study of Plozasiran in Adults With Severe HypertriglyceridemiaArrowhead Pharmaceuticals · Severe HypertriglyceridemiaCompletedARWRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 12, 2026ActualPhase 3NCT06347003Study of Plozasiran (ARO-APOC3) in Adults With Severe HypertriglyceridemiaArrowhead Pharmaceuticals · Severe HypertriglyceridemiaCompletedARWRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2029Sponsor estimatePhase 2NCT07859813A Trial to Evaluate the Efficacy and Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Associated SteatohepatitisArrowhead Pharmaceuticals · Metabolic Dysfunction-Associated SteatohepatitisNot yet recruitingARWRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 2NCT07241546Study of Inhaled ARO-RAGE in Allergen-induced Mild AsthmaArrowhead Pharmaceuticals · AsthmaRecruitingARWRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2028Sponsor estimatePhase 3NCT06822790Long-Term Safety and Efficacy of Plozasiran in Adults With HypertriglyceridemiaArrowhead Pharmaceuticals · HypertriglyceridemiaActive, not recruitingARWRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 1, 2026ActualPhase 3NCT06347133Phase 3 Study of Plozasiran in Adults With HypertriglyceridemiaArrowhead Pharmaceuticals · HypertriglyceridemiaCompletedARWRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2029Sponsor estimatePhase 3NCT06880770Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute PancreatitisArrowhead Pharmaceuticals · Severe HypertriglyceridemiaRecruitingARWRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 1, 2028Sponsor estimatePhase 1NCT07662096A First-In-Human Study of ARO-033 in Adult ParticipantsArrowhead Pharmaceuticals · Age-related Macular DegenerationRecruitingARWRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 12, 2024ActualPhase 1/Phase 2NCT05292950Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung DiseaseArrowhead Pharmaceuticals · AsthmaTerminatedARWRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 20, 2027Sponsor estimatePhase 3NCT07037771A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)Arrowhead Pharmaceuticals · Homozygous Familial HypercholesterolemiaActive, not recruitingARWRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 5, 2025ActualPhase 1/Phase 2NCT05537025Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary FibrosisArrowhead Pharmaceuticals · Idiopathic Pulmonary FibrosisCompletedARWRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2027Sponsor estimatePhase 1/Phase 2NCT06937203A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes MellitusArrowhead Pharmaceuticals · ObesityRecruitingARWRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT06672445Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2Arrowhead Pharmaceuticals · Spinocerebellar Ataxia Type 2Active, not recruitingARWRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2, 2023ActualPhase 2NCT05217667Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)Arrowhead Pharmaceuticals · Homozygous Familial HypercholesterolemiaTerminatedARWRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2025ActualPhase 1NCT06209177Study of ARO-CFB in Adult Healthy VolunteersArrowhead Pharmaceuticals · IgA NephropathyCompletedARWRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 10, 2025ActualPhase 1/Phase 2NCT05083364Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal DiseaseArrowhead Pharmaceuticals · C3 GlomerulopathyCompletedARWRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 29, 2024ActualPhase 3NCT05089084Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)Arrowhead Pharmaceuticals · Familial ChylomicronemiaCompletedARWRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 22, 2025ActualPhase 2NCT05413135Study of ARO-APOC3 in Adults With DyslipidemiaArrowhead Pharmaceuticals · DyslipidemiasCompletedARWRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 10, 2023ActualPhase 2NCT04998201Study of Plozasiran (ARO-APOC3) in Adults With Mixed DyslipidemiaArrowhead Pharmaceuticals · Mixed DyslipidemiaCompletedARWRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 16, 2025ActualPhase 1/Phase 2NCT05276570Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung DiseaseArrowhead Pharmaceuticals · AsthmaCompletedARWRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 9, 2023ActualPhase 2NCT04720534Study to Evaluate ARO-APOC3 in Adults With Severe HypertriglyceridemiaArrowhead Pharmaceuticals · Severe HypertriglyceridemiaCompletedARWRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 27 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner